cases of endocarditis due to S. bovis and 21.1% of PVE cases. A significant increase in cases has occurred in recent years. Thus, although there were no such cases among the 24 cases of endocarditis due to S. bovis from 1988 to 2001, there were 23 cases out of 88 (26.1%) (P < .02) from 2002 to 2015. This increase coincided with an increase in valve surgery in our area during this period. A total of 82.6% (19/23) of the cases occurred more than 1 year after the prosthesis was implanted (mean 75 ± 63.6 months). S. bovis was the second leading cause of PVE after staphylococci (38 cases), and the leading cause of late PVE. Of the 103 cases of endocarditis due to S. bovis biotype I (S. gallolyticus subsp. gallolyticus), 17 were PVE (16.5%), whereas 6 of the 9 (66.6%) cases caused by S. bovis biotype II were PVE [5 due to S. bovis biotype II/1 (S. infantarius) and 1 due to S. bovis biotype II/ 2 (S. pasteurianus); P < .001].
The characteristics of these cases of endocarditis are listed in Table 1 . The patients with PVE due to S. bovis had a higher mean age, greater aortic involvement, and more paravalvular complications, whereas those with native valve endocarditis had longer lasting symptoms, greater multivalvular involvement, and a higher rate of embolisms. However, there were no significant differences in terms of the presence of heart failure, mortality, and the need for surgery, both during the episode and at 1 year.
In conclusion, PVE due to S. bovis is a condition that appears to be growing in prevalence in our center and is only exceeded by staphylococci in the number of cases. PVE due to S. bovis do not have more complications or a poorer prognosis than those with native valve endocarditis. Our data suggest that endocarditis due to the biotype II has a greater propensity to affect the prosthesis than S. gallolyticus subsp. gallolyticus. Studies with larger series are needed to confirm these findings.
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